GHK-Cu is an endogenous copper-binding tripeptide, first described from human plasma albumin and also sourced through SPARC and proteolysis. Its amino acid sequence is glycine, histidine, lysine bound to copper, and its affinity for copper exceeds that of albumin. In the skin context, this lesson looks at how the peptide is applied topically for resilience and how the same mechanisms can be approached systemically.

The topical use sits in a defined regulatory space. GHK-Cu is not approved for human-use indications and has no approved systemic use, but it is permitted cosmetically as Copper Peptide-1 at concentrations from 0.01% to 1%, provided the cosmetic labeling does not reference the molecular mechanisms discussed here. It is compounded as a serum or cream for topical use and subcutaneously, though there is no published IV data.

How it works in skin

In the extracellular matrix, GHK-Cu increases collagen types I and III, elastin, and glycosaminoglycans across preclinical and human studies. It modulates the TGF-beta and SMAD pathway in a context-dependent way, acting as a connective-tissue modulator that can shift between antifibrotic and pro-regenerative modes depending on the tissue state. It inhibits NF-kB by blocking P65 translocation, which lowers TNF-alpha, IL-6, and IL-1 beta in preclinical work, and it activates the NRF2-ARE antioxidant pathway, raising superoxide dismutase and glutathione peroxidase expression. As a copper tripeptide it also helps silence copper redox chemistry by binding copper tightly rather than leaving it free.

Human evidence and the inside-out approach

Topical human studies have reported improved skin firmness, density, and thickness, with reduced fine lines and wrinkles over eight to twelve weeks. Collagen production has been noted to increase in skin biopsies, and one randomized double-blind study reported reduced wrinkle volume. Decades of cosmetic use show a favorable safety profile, with only transient redness or irritation and rare allergic reactions reported.

The systemic, or inside-out, approach targets the same fibroblasts, keratinocytes, and melanocytes from within. Reported subcutaneous dosing ranges from 0.5 to 2.5 mg, often cycled on and off. Systemic safety, human pharmacokinetics, and large-scale controlled data remain unconfirmed, so this register stays clearly separated from the validated topical use.

Key clinical points

• GHK-Cu is an endogenous copper-binding tripeptide (glycine-histidine-lysine) with copper affinity exceeding albumin.
• Topical cosmetic use is permitted at 0.01% to 1% as Copper Peptide-1; it is not approved for systemic indications.
• Mechanisms include matrix collagen and elastin support, context-dependent TGF-beta/SMAD modulation, NF-kB inhibition, and NRF2-ARE antioxidant activation.
• Human evidence supports skin and cosmetic use; systemic safety and human pharmacokinetics are unconfirmed.
• Distinguish validated topical use from unvalidated systemic extrapolation when applying this clinically.